Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
Want to see IN:GLENMARK full AI Analyst Report?
Total Valuation
Glenmark Pharmaceuticals Limited has a market cap or net worth of ₹605.14B. The enterprise value is ₹627.75B.
Market Cap₹605.14B
Enterprise Value₹627.75B
Share Statistics
Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding282,200,800
Owned by Insiders―
Owned by Institutions0.05%
Financial Efficiency
Glenmark Pharmaceuticals Limited’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 20.12%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)20.12%
Return on Capital Employed (ROCE)0.30
Revenue Per Employee11.33M
Profits Per Employee908.57K
Employee Count14,989
Asset Turnover0.85
Inventory Turnover2.59
Valuation Ratios
The current PE Ratio of Glenmark Pharmaceuticals Limited is 44.4. Glenmark Pharmaceuticals Limited’s PEG ratio is 1.47.
PE Ratio44.4
PS Ratio3.54
PB Ratio5.72
Price to Fair Value5.72
Price to FCF30.98
Price to Operating Cash Flow21.34
PEG Ratio1.47
Income Statement
In the last 12 months, Glenmark Pharmaceuticals Limited had revenue of 169.83B and earned 13.62B in profits. Earnings per share was 48.26.
Revenue169.83B
Gross Profit80.84B
Operating Income39.99B
Pretax Income19.85B
Net Income13.62B
EBITDA27.67B
Earnings Per Share (EPS)48.26
Cash Flow
In the last 12 months, operating cash flow was 28.36B and capital expenditures -5.00B, giving a free cash flow of 23.35B billion.
Operating Cash Flow28.36B
Free Cash Flow23.35B
Free Cash Flow per Share82.75
Dividends & Yields
Glenmark Pharmaceuticals Limited pays an annual dividend of ₹2.5, resulting in a dividend yield of 0.24%
Dividend Per Share₹2.5
Dividend Yield0.24%
Payout Ratio11.28%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change31.25%
50-Day Moving Average2.26K
200-Day Moving Average2.06K
Relative Strength Index (RSI)38.49
Average Volume (3m)28.97K
Important Dates
Glenmark Pharmaceuticals Limited upcoming earnings date is Aug 7, 2026, During Market Hours (Confirmed).
Last Earnings DateMay 29, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Glenmark Pharmaceuticals Limited as a current ratio of 1.77, with Debt / Equity ratio of 5.65%
Current Ratio1.77
Quick Ratio1.23
Debt to Market Cap<0.01
Net Debt to EBITDA-0.13
Interest Coverage Ratio19.16
Taxes
In the past 12 months, Glenmark Pharmaceuticals Limited has paid 6.23B in taxes.
Income Tax6.23B
Effective Tax Rate0.31
Enterprise Valuation
Glenmark Pharmaceuticals Limited EV to EBITDA ratio is 13.03, with an EV/FCF ratio of 30.68.
EV to Sales3.51
EV to EBITDA13.03
EV to Free Cash Flow30.68
EV to Operating Cash Flow18.06
Balance Sheet
Glenmark Pharmaceuticals Limited has ₹29.58B in cash and marketable securities with ₹12.24B in debt, giving a net cash position of ₹17.34B billion.
Cash & Marketable Securities₹29.58B
Total Debt₹12.24B
Net Cash₹17.34B
Net Cash Per Share₹61.45
Tangible Book Value Per Share₹283.69
Margins
Gross margin is 47.60%, with operating margin of 23.55%, and net profit margin of 8.02%.
Gross Margin47.60%
Operating Margin23.55%
Pretax Margin11.69%
Net Profit Margin8.02%
EBITDA Margin26.92%
EBIT Margin23.55%
Analyst Forecast
The average price target for Glenmark Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast27.48%
EPS Growth Forecast30.05%